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Abstract 
Kallikrein-related peptidases, in particular KLK4, 5, 6 and 7 (4–7), often have 
elevated expression levels in ovarian cancer. In OV-MZ-6 ovarian cancer cells, 
combined expression of KLK4–7 reduces cell adhesion and increases cell 
invasion and resistance to paclitaxel. The present work investigates how 
KLK4–7 shape the secreted proteome (“secretome”) and proteolytic profile 
(“degradome”) of ovarian cancer cells. The secretome comparison 
consistently identified > 900 proteins in three replicate analyses. Expression 
of KLK4–7 predominantly affected the abundance of proteins involved in cell-
cell communication. Among others, this includes increased levels of 
transforming growth factor β-1 (TGFβ-1). KLK4–7 co–transfected OV-MZ-6 
cells share prominent features of elevated TGFβ-1 signaling, including 
increased abundance of neural cell adhesion molecule L1 (L1CAM). 
Augmented levels of TGFβ-1 and L1CAM upon expression of KLK4 – 7 were 
corroborated in vivo by an ovarian cancer xenograft model. The degradomic 
analysis showed that KLK4–7 expression mostly affected cleavage sites C-
terminal to arginine, corresponding to the preference of kallikreins 4, 5 and 6. 
Putative kallikrein substrates include chemokines, such as growth 
differentiation factor 15 (GDF 15) and macrophage migration inhibitory factor 
(MIF). Proteolytic maturation of TGFβ-1 was also elevated. KLK4–7 have a 
pronounced, yet non-degrading impact on the secreted proteome, with a 
strong association between these proteases and TGFβ-1 signaling in tumor 
biology. 
(217 words) 
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Highlights 
• Expression of KLK4, 5, 6, and 7 yields subtle secretome and 
degradome alterations 
• Pro- and anti-tumorigenic proteins are affected  
• TGFβ–1 signaling is elevated 
• Degradomic analysis supports cell-contextual KLK activity 
• Potential substrates of KLK4–7 have been identified 
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1 Introduction 
Ovarian cancer accounts for 6 % of all cancer-related deaths despite its 
comparably low incidence rate (3 % of solid tumors) (Siegel et al., 2012). 
90 % of ovarian cancers are of epithelial origin. Most women present with 
advanced stage disease since they often remain asymptomatic in the early 
stage disease. Hence, the prognosis is poor with five-year survival rates < 
20 % (Roett and Evans, 2009). Kallikrein-related peptidases (KLKs) are 
frequently over-expressed in ovarian cancer (Borgoño et al., 2004) and are 
suggested to be prognostic markers (Obiezu and Diamandis, 2005). They 
solely comprise a catalytic domain of approximately 25 kDa and have trypsin-
like or chymotrypsin–like specificity (Yousef and Diamandis, 2003).  
 
During the last decade, a series of publications showed strong linkage 
between poor prognosis in ovarian cancer and elevated expression of KLK 
proteases, including human KLK 4 (Dong et al., 2001; Obiezu et al., 2001; Xi 
et al., 2004), KLK5 (Diamandis et al., 2003; Kim et al., 2001; Michael et al., 
2005; Yousef et al., 2003a; Yousef et al., 2003b), KLK6 (Diamandis et al., 
2003; Diamandis et al., 2000; Ghosh et al., 2004; Hoffman et al., 2002; 
Kountourakis et al., 2008; Lu et al., 2004; Ni et al., 2004; Santin et al., 2004; 
Shih Ie et al., 2007; Tanimoto et al., 2001; White et al., 2009), and KLK7 
(Kyriakopoulou et al., 2003; Psyrri et al., 2008; Shan et al., 2006; Shigemasa 
et al., 2001; Shih Ie et al., 2007; Tanimoto et al., 1999). 
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There exists comparably few data on the causative relation between KLK 
expression and aggressiveness of this disease. One of the first studies to 
investigate the impact of KLK proteases on tumor cell behavior used the 
ovarian cancer cell line OV-MZ-6, which lacks endogenous KLK expression. 
OV-MZ-6 were co-transfected to express KLK4–7 simultaneously (Prezas et 
al., 2006). Combined expression of KLK4–7 led to increased invasiveness in 
in vitro matrigel invasion assays and elevated tumor burden in a xenograft 
model (Prezas et al., 2006). Noteworthy, expression levels of KLK4–7 were 
moderate, with antigen levels in the low ng / ml range in cell culture 
supernatant, xenograft tumor tissue and tumor fluid. A recent follow-up study 
showed that combined KLK4–7 expression decreases cell adhesion to 
vitronectin and fibronectin while the resistance to paclitaxel, a cytotoxic agent 
which is used as a chemotherapeutic for ovarian cancer, was increased 
(Loessner et al., 2012). In good agreement, several studies revealed that 
expression of KLK4–7 correlated with the lack of response to paclitaxel in 
ovarian cancer patients (Dong et al., 2010; Oikonomopoulou et al., 2008; Xi et 
al., 2004; Yousef and Diamandis, 2009). 
As a post-translational modification, proteolysis acts in both destructive and 
constructive manner. “Destructive” describes degradative function of 
proteolysis. In this context, proteolysis is important for adjusting proteome 
composition and protein turnover. “Constructive” refers to limited proteolysis, 
which generates stable cleavage products that often possess new 
functionality; examples include activation of enzyme and cytokine precursors 
as in the case of transforming growth factor β–1 (TGFβ-1). 
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Despite numerous studies that correlate KLK expression with cancer 
progression, it has remained largely unknown how they shape the 
extracellular proteome and which proteolytic cleavage events are mediated by 
their expression. Mass spectrometry-based proteomics is a very powerful 
approach to quantitatively survey proteome composition in different biological 
samples (Aebersold and Mann, 2003). However, such global approaches are 
not well suited for the analysis of native or proteolytically generated protein 
termini as these are typically overshadowed by more abundant native 
peptides. Hence, specific enrichment techniques are employed to accumulate 
terminal peptides. Proteomic strategies targeting proteolytic processing are 
referred as ‘degradomics’ (López-Otín and Matrisian, 2007). One of the most 
powerful degradomic approaches, targeting protein N-termini, has been 
brought forward by Kleifeld et al (Kleifeld et al., 2010) with widespread 
applications in cell cultures (Jefferson et al., 2013; Prudova et al., 2010; 
Tholen et al., 2011) and tissue samples (auf dem Keller et al., 2013; Tholen et 
al., 2013). Typically, secretome or proteome composition is studied in parallel 
by a global, quantitative proteomics approach employing stable isotope 
labeling. The combination of both strategies is crucial since protease (over-) 
expression often leads to downstream effects and altered protein abundance. 
Cleavage sites in quantitatively affected proteins may appear as up- or down-
regulated; however, they rather represent altered protein abundance than 
affected proteolysis. 
It has been shown that KLK proteases, including KLK4, 5, 6 and 7, degrade 
components of the extracellular matrix (ECM) in vitro (Ghosh et al., 2004; 
Michael et al., 2005; Obiezu et al., 2006; Ramani and Haun, 2008). However, 
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in vitro studies using purified proteases and individual substrate candidates 
are intrinsically biased and fail to depict cell–contextual proteolysis. The in 
vivo context differs considerably from the in vitro situation through the 
presence of co-factors, inhibitors, and the occurrence of downstream effects, 
such as perturbed activation cascades. Using the KLK4–7 co-transfected OV–
MZ-6 cells, this study investigates how KLK4-7 contribute to the extracellular 
proteome composition and which proteolytic cleavage events are affected. 
Motivated by their important roles in ovarian cancer, this is the first cell–
contextual proteomic and degradomic study of kallikrein proteases. Our 
results highlight extracellular kallikrein activity, albeit without massively 
elevated degradative proteolysis. Importantly, expression of KLK4–7 leads to 
elevated TGFβ–1 signaling with concurrent effects, such as increased L1CAM 
expression, and a previously described more motile cellular phenotype 
(Loessner et al., 2012; Prezas et al., 2006). 
 
2 Materials and Methods 
2.1 Cell Culture 
The human ovarian cancer cell line OV–MZ-6 was established from the tumor 
fluid (ascites) of a patient with serous adenocarcinoma of the ovary (Mobus et 
al., 1992) and used to stably co-transfect expression vectors harboring human 
full-length cDNA of kallikreins 4–7 (Prezas et al., 2006). OV-MZ-6 cells 
transfected with an empty vector served as controls. Cells were cultured in 
Dulbecco’s modified eagle medium (DMEM; PAN) supplemented with 10 % 
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fetal calf serum (FCS; PAN), 1 % non-essential amino acids, 1 % MEM 
vitamins, 1 % penicillin/streptomycin, and 10 mM HEPES (pH 7.5) at 37 °C in 
humidified air containing 5 % CO2. 
 
2.2 Collection of Cell Conditioned Medium for Proteomic 
and Degradomic Analyses 
Cell conditioned medium (CCM) was generated by incubation of cells in 
serum-free medium to avoid overshadowing of serum proteins. Cells were 
grown to 90 % confluency as described above. The medium was removed, 
and cells were washed thrice with DMEM (without phenol red and FCS). Cells 
were then incubated in DMEM (1 % non-essential amino acids, 1 % MEM 
vitamins, 1 % penicillin/streptomycin, 10mM HEPES (pH 7.5); without phenol 
red) for one hour at 37 ºC. Then, this medium was removed, and the cells 
were gently washed twice with DMEM (without phenol red and FCS) and 20 
ml of fresh serum-free medium (as above) added. After 24 hours, the CCM 
was harvested, and protease-inhibitors were added [1 µM trans-
epoxysuccinyl-L-leucylamido(4-guanidino)butane (E–64), 5 mM ethylene-
diaminetetraacetic acid (EDTA), 1 mM phenlymethansulfonylflouride (PMSF)]. 
Cell debris was removed by centrifugation at 4500 rpm for 5 min at 4 ºC and 
filtration through a 0.2 µm syringe filter. Protein concentration was determined 
using a Bradford (Bio-Rad) or bicinchonic acid (BCA) assay. 
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2.3 Quantitative Proteome Comparison 
Quantitative proteome comparison by differential dimethylation was performed 
as described previously (Tholen et al., 2013; Tholen et al., 2011). Briefly, 
CCM was concentrated by ultra-filtration (5 kDa molecular weight cut-off 
(MWCO; Vivascience) followed by precipitation with acetone–methanol or 
trichloracetic acid. The protein pellet was re-solubilized in ice-cold 100 mM 
NaOH using ultrasonication. After adjusting the pH to 8.0 using HEPES, the 
samples were trypsinized (1:100; sequencing grade trypsin, Worthington; for 
16 h at 37 °C), reduced (2 mM tris(2-carboxyethyl)phosphine (TCEP; Sigma), 
one hour at 37 °C), and alkylated (10 mM iodoacetamide (Sigma) at 37 °C for 
one hour followed by 5 mM dithiothreitol (DTT; Sigma), 20 min at 22 °C for 
quenching). Isotopic labels were introduced by reductive dimethylation of 
primary amines using either light (12COH2; Sigma) or heavy (13COD2; 
Cambridge Isotopes) formaldehyde (FA). Samples were incubated with 20 
mM of the given formaldehyde isotope and 20 mM of sodium 
cyanoborohydride (ALD coupling solution, Sterogene) for 16 h at 37 °C. 
Excess reagents were quenched with 20 mM glycine (20 min, 22 °C). Equal 
amounts of heavy and light labeled samples were mixed, desalted using C18 
solid phase extraction (Waters) according to manufacturer’s instruction, and 
fractionated by strong cation exchange (SCX) chromatography as described 
previously (Tholen et al., 2011) prior to liquid chromatography - tandem mass 
spectrometry (LC-MS/MS) analysis (see corresponding section). 
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2.4 Terminal Amine Isotopic Labeling of Substrates 
Terminal Amine Isotopic Labeling of Substrates (TAILS) (Kleifeld et al., 2010) 
was performed as described previously (Tholen et al., 2013; Tholen et al., 
2011). Briefly, the CCM was concentrated by ultrafiltration (5 kDa MWCO) 
followed by precipitation with acetone–methanol or trichloracetic acid. The 
protein pellet was re-solubilized in ice-cold 100 mM NaOH and 3 M guanidine 
hydrochloride using ultrasonication. After adjusting the pH to 8.0 using 
HEPES, the samples were reduced (5 mM DTT for one hour at 37 °C), 
alkylated (15 mM iodoacetamide in the dark for 30 min at 22 °C) with 
quenching of excess iodoacetamide (5 mM DTT for 30 min at 22 °C). 
Samples were labeled by dimethylation using 20 mM light (12COH2; Sigma) or 
heavy (13COD2; Cambridge Isotopes) formaldehyde in the presence of 20 mM 
NaCNBH3 (for 18 h at 37 °C). After quenching of excess reagents with 50 mM 
Tris-Cl, pH 7.5 (for 1 h at 37 °C), samples were mixed at equal amounts, 
acetone precipitated and re-solubilized with 100 mM ice–cold NaOH as 
described for quantitative proteome comparison. The pH was adjusted to 8.0 
with HEPES-free acid, trypsinized (1:100; for 18 h at 37 °C), and purified 
using Sep-Pak C18 solid-phase extraction columns (Waters) according to 
manufacturer’s instructions. Samples were eluted in 80 % acetonitrile, pH was 
adjusted to 7.0 and acetonitrile removed by vacuum evaporation, followed by 
volume adjustment with water. Internal peptides bearing free N-termini were 
coupled to an aldehyde-functionalized polymer (Kleifeld et al., 2010) in the 
presence of 50 mM sodium cyanoborohydride (Sterogene). Excess reagents 
were quenched with 100 mM glycine for one hour at room temperature. The 
sample was applied to a 10 kDa MWCO filter. The flow–through was desalted, 
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fractionated by strong cation exchange (SCX) chromatography, and analyzed 
by LC-MS/MS. 
 
2.5 LC-MS/MS Analysis 
For nanoflow-LC-MS/MS analysis, samples for quantitative proteomic 
comparison were analyzed on a Qstar Elite (AB Sciex) and TAILS samples for 
quantitative proteomic comparison on an Orbitrap XL (Thermo Scientific 
GmbH) mass spectrometer. Both instruments were coupled to an 
Ultimate3000 micro pump (Thermo Scientific) with a flow rate of 300 nl / min 
each. Buffer A was 0.5 % acetic acid, and buffer B was 0.5 % acetic acid in 
80 % acetonitrile (water and acetonitrile were at least HPLC gradient grade 
quality). A gradient of increasing organic proportion was used for peptide 
separation. Column-tips with 75 µm inner diameter and a length of 11 cm 
were self-packed (Olsen et al., 2004) with Reprosil-Pur 120 ODS-3 (Dr. 
Maisch, Ammerbuch, Germany). The MS operated in data dependent mode, 
with the SMART being used for the QSTAR Elite. For the Orbitrap XL, each 
MS scan was followed by a maximum of five MS/MS scans; in case of the 
Qstar Elite of three MS/MS scans. 
 
2.6 LC-MS/MS Data Analysis: Quantitative Proteome 
Comparison 
Raw QSTAR LC-MS/MS data in wiff format was converted to the mzXML 
(Pedrioli et al., 2004) format, using mzWiff (version 4.3.1, 
http://sourceforge.net/projects/sashimi/files/mzWiff%20(Analyst%20converter), 
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with centroiding of MS1 and MS2 data, precursor charge determination, and 
deisotoping of MS2 data. For spectrum to sequence assignment X! Tandem 
(version 2010.12.01) (Craig and Beavis, 2004) was used. The proteome 
database consisted of human reviewed canonical uniprot sequences (without 
isoforms) downloaded from UniProt on February 28, 2012. It consists of 
20,240 real protein entries. It was appended with an equal number of shuffled 
decoy entries derived from the original human protein sequences. The decoy 
sequences were generated with the software DB toolkit (Martens et al., 2005). 
Two different searches were conducted for light and heavy labeled peptides. 
X! Tandem parameters included: asymmetric pre-cursor mass error of 0-200 
ppm, fragment ion mass tolerance of 0.2 Da, tryptic cleavage specificity with 
no missed cleavage sites, residue modifications: cysteine 
carboxyamidomethylation (+57.02 Da), lysine and N-terminal dimethylation 
(light formaldehyde 28.03 Da; heavy formaldehyde 34.06 Da); no variable 
modifications. X! Tandem results were further validated by PeptideProphet 
(Keller et al., 2002) at a confidence level of > 95 %. Peptides were assembled 
to proteins using ProteinProphet (Nesvizhskii et al., 2003). For relative peptide 
and protein quantification ASAPRatio (Li et al., 2003) was used. ASAPRatio 
results were validated by XPRESS (Han et al., 2001) as described previously 
(Tholen et al., 2013). Proteins were only considered if ASAPratio and 
XPRESS yielded convergent results. Mass tolerance for quantification was 
0.1 Da. Ratios of each dataset were calculated as KLK expression over 
controls. ASAPratio data was log2-transformed. ASAPRatio p-values were 
merged using Fisher’s exact test. A combined p-value was calculated 
according to the !2" distribution." Protein abundance was considered to be 
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significantly altered if the following conditions were met: (A) the protein was 
identified in all three replicate experiments, (B) merged ASAPRatio p-value < 
0.1, (C) protein abundance was either increased or decreased in all three 
replicate experiments. Since this work focuses on secreted proteins, only the 
secreted proteins were further considered. A protein was considered to be 
secreted or cell surface localized if its GO (Gene Ontology) cellular 
compartment information or its SwissProt localization information featured one 
of the following terms: secreted, extracellular, surface, integral to membrane. 
 
2.7 LC-MS/MS Data Analysis: Terminal Amine Isotopic 
Labeling of Substrates 
Orbitrap LC-MS/MS data in raw format was converted to the mzXML (Pedrioli 
et al., 2004) format, using msconvert (Kessner et al., 2008) with centroiding of 
MS1 and MS2 data, and deisotoping of MS2 data. For spectrum to sequence 
assignment X! Tandem (Version 2010.12.01) (Craig and Beavis, 2004) was 
used with the same database described for “LC-MS/MS Data Analysis: 
Quantitative Proteome Comparison”. Two different searches were conducted 
for light and heavy labeled peptides. X! Tandem parameters included: pre-
cursor mass error of ± 10 ppm, fragment ion mass tolerance of 0.3 Da, semi-
specific cleavage C-terminal to arginine residues (“Semi Arg-C specificity”) 
with up to three missed cleavages, residue modifications: cysteine 
carboxyamidomethylation (+57.02 Da), lysine and N-terminal dimethylation 
(light formaldehyde 28.03 Da; heavy formaldehyde 34.06 Da); no variable 
modifications. X!Tandem results were further validated by PeptideProphet 
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(Keller et al., 2002) at a confidence level of > 95 %. For relative peptide and 
protein quantification ASAPRatio (Li et al., 2003) was used. ASAPRatio 
results were validated by XPRESS (Zhang et al., 2003) as described 
previously (Tholen et al., 2013). Peptides were only considered if ASAPratio 
and XPRESS yielded convergent results. Two TAILS experiments were 
performed. Ratios of each dataset were calculated as KLK expression over 
controls. Ratios were divided into the following quantiles 0 – 20, 20 – 80, and 
80 – 100. N–termini were considered as decreased if found in the quantile 0 - 
20 in both replicates or as increased if found in the quantile 80 – 100 in both 
replicates. Further analysis focused particularly on secreted proteins as 
described in “LC-MS/MS Data Analysis: Quantitative Proteome Comparison”. 
 
2.8 Western Blotting 
The CCM was prepared as described above. Total cell extracts were 
prepared by on plate lysis with 50 mM Tris−Cl, pH 8.0, 150 mM NaCl, 0.5 % 
sodium deoxycholate, 0.1 % SDS. Samples were separated by SDS-
polyacrylamide gels (see Figures for details) and transferred on polyvinylidene 
fluoride (PVDF) membrane using a semidry blotting system (BioRad). Primary 
antibodies [PEDF (1:1000, R&D Systems, AF1177), L1CAM (1:1000, R&D 
Systems, AF277); LAP (TGFβ–1 prodomain) (1:1000, R&D Systems, 
AF246NA); tubulin (1:1000, Sigma, T6199), TGFβ–1 (1:200, R&D Systems, 
AF7555)] were incubated for 18 h at 4° C. After washing, the membranes 
were incubated for 18 h at 4° C with horseradish peroxidase–coupled 
secondary antibodies (goat, Dianova or sheep, Sigma). After further washing, 
the membranes were developed with the West Pico chemiluminescent 
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substrate (Pierce), and peroxidase activity detected with a LumiImager device 
(Roche). 
 
2.9 Immunohistochemical Analysis of Tumor Xenografts 
To evaluate the relevance of LAP/TGFβ-1 and L1CAM expression in vivo, 
serial sections (5 µm) of tumor xenografts derived from a recently developed 
ovarian cancer animal model (Loessner et al., 2013) were obtained and 
immunohistochemically processed. Briefly, antigen retrieval was performed by 
95 ºC treatment in 0.01 M Tris-EDTA buffer (pH 8.0) followed by incubation of 
anti-LAP (R&D Systems, AF246NA) and anti-L1CAM (R&D Systems, AF277) 
antibodies (5 µg/ml) for one hr at room temperature. The horseradish 
peroxidise (anti-goat) polymer detection system with 3,3’-diaminobenzidine as 
the chromogen (R&D Systems) was used. Sections were counterstained with 
Mayer’s hematoxylin. Goat IgG (Sigma-Aldrich) replacing the primary 
antibodies served as negative control. Human-derived liver metastasis served 
as positive control staining imaged using a widefield microscope (LaborLux, 
Leitz; DXM1200C digital camera, Nikon; ACT–1C software v.1.01) with a 20x 
air objective. 
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3 Results and Discussion 
3.1 Global Proteome Comparison 
3.1.1 Overview and Overlap of Individual Replicates 
Since KLKs are secreted proteases, we initially aimed to investigate how their 
expression modifies the extracellular proteome composition of ovarian cancer 
cells. Three replicates were performed for the global secretome comparison. 
In each case, CCM from KLK4-7 co-transfected OV–MZ-6 cells was 
compared to CCM of controls. Differential labeling with isotopic formaldehyde 
variants was performed for quantitative comparison. These experiments 
identified and quantified 1,390, 1,474, and 1,477 proteins respectively (Sup. 
Tables S1 – S3). Based on gene ontology (GO) and SwissProt annotation the 
fraction of secreted and/or cell surface-associated proteins was 26 − 27 %. 
These values correspond well to the fraction of extracellular and/or 
transmembrane proteins that were identified from the CCM of lung cancer 
cells (Planque et al., 2009), breast cancer cells (Kulasingam and Diamandis, 
2007) and mouse embryonic fibroblasts (Tholen et al., 2011). In each 
replicate, the fold–change (Fc) values (log2 of light to heavy ratios) followed a 
near normal distribution with most proteins displaying none or very little 
quantitative alteration (Figure 1a – c). These findings suggest that expression 
of KLK4-7 results in subtle proteome alterations rather than gross degradation. 
 
In order to delineate consistent proteome changes as a result of KLK 
expression, this work focuses on proteins that were identified across all three 
replicates. In total, this was the case for 928 proteins (Figure 1d, Sup. Table 
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S4), of which 273 are annotated as being secreted or cell surface-associated. 
The three replicates displayed a high reproducibility of protein quantitation 
with correlation coefficients between 0.67 and 0.80 (not shown). 
 
3.1.2 Quantitatively Affected Proteins 
Chemical stable isotope labeling was used to allow for relative quantitation of 
peptides and proteins. The software ASAPRatio was used to calculate peptide 
ratios together with a p–value to denote the statistical significance of a protein 
being quantitatively affected (Li et al., 2003). ASAPRatio p–values of the three 
replicates were combined as previously described (Tholen et al., 2013) to 
yield a merged p-value. Proteins were considered as being quantitatively 
affected if the merged p-value was less than 0.1 in agreement with the original 
ASAPRatio publication (Keller et al., 2002). Secondly, an increase or 
decrease by more than 50% in all three replicates must be observed. Lastly, 
peptide and protein ratios were manually inspected. Of the 273 potentially 
secreted or shed proteins that were identified in all three replicates, 45 
proteins fulfilled these criteria (Table 1). 
 
Out of the 45 significantly affected proteins, 39 were increased in abundance 
and only 6 were decreased in abundance. These findings suggest that 
kallikreins 4-7 expression does not result in major degradation, although 
biochemically various kallikreins are able to degrade proteins, such as insulin 
growth factor binding proteins (IGFBPs) (Matsumura et al., 2005). Rather, 
KLK4-7 expression appears to regulate cell-cell communication. This notion 
was supported upon closer inspection of the affected proteins. Examples of 
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affected proteins with roles in cell−cell communication include IGFBP–3 and –
6, semaphorins 3A and 6C, osteoprotegerin, dickkopf-related protein 1 (DKK–
1), C–X–C motif chemokine 1 (CXCL1), macrophage colony stimulating factor 
1 (MCSF-1), pigment epithelium-derived factor (PEDF), latent TGFβ binding 
protein 3 (LTGFBP–3), and TGFβ–1. 
 
On the other hand, only few ECM components or matricellular proteins were 
affected, such as cochlin, laminin β2, collagens XVIII and V. For collagen 
XVIII, almost all identified peptides mapped to its non-collagenous C-terminal 
domain, which includes the anti-angiogenic cleavage product endostatin 
(Figure 2). Similarly, for collagen V, almost all identified peptides mapped to 
its non-collagenous C-terminal prodomain (data not shown). These 
observations highlight the importance of peptide mapping for the functional 
interpretation of proteomic data. 
 
To support our quantitative proteomic results, we validated the differential 
ratios for PEDF, thrombospondin–1, L1CAM, and TGFβ–1 by immunoblotting. 
For all four proteins, immunoblotting results are in line with quantitative 
proteomic results (Figure 3). PEDF massively increases in abundance upon 
combined expression of KLK4–7 (Figure 3a) whereas thrombospondin–1 
levels decrease (Figure 3b). L1CAM, and TGFβ–1 are discussed in detail 
below. 
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A vast body of literature links kallikrein expression to unfavorable prognosis in 
different tumor entities (see also Introduction). Based on this general picture, 
we investigated, whether affected proteins rather bear a pro– or anti–
tumorigenic signature. However, a predominant pro- or anti-tumorigenic effect 
of KLK expression was not detected. For example, the group of proteins with 
increased abundance features tumor suppressors such as PEDF (Becerra 
and Notario, 2013) as well as tumor-promoting proteins, such as DKK–1 
(Pinzone et al., 2009; Yang et al., 2013). The present data shows a prominent 
effect of KLK 4–7 expression on proteins with relevant roles in tumor biology 
but without a clear pro– or anti–tumorigenic signature. Accordingly, the 
proteomic data does not necessarily imply that expression of KLK 4–7 has a 
predominant pro–tumorigenic effect.  
  
3.1.3 Transforming Growth Factor β-1 Signaling 
TGFβ–1 plays a central role in cancer biology. The biological and cellular 
context determines the role of TGFβ–1 in tumorigenesis, which can be either 
tumor-promoting or tumor-suppressing (Joshi and Cao, 2010). In early stages 
of tumorigenesis, TGFβ–1 is thought to be tumor suppressive through pro-
apoptotic activity. In later stages of tumorigenesis, TGFβ–1 is thought to 
facilitate metastasis by promoting cell migration and invasion in a process 
resembling an epithelial–mesenchymal transition (EMT) (Heldin et al., 2012). 
 
TGFβ–1 is synthesized as an inactive precursor with an N-terminal prodomain 
(also called latency-associated protein, LAP), which is proteolytically removed 
for activation of the C–terminal TGFβ–1 domain. Cleavage is typically 
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performed by furin-like proteases (Dubois et al., 1995), although activating 
cleavage by KLK proteases has been suggested (Emami and Diamandis, 
2007; Matsumura et al., 2005). LAP covalently binds to LTGFBPs through 
disulfide bonds (Hyytiäinen et al., 2004). LTGFBPs further bind to ECM 
proteins, thereby spatially fixing latent TGFβ. In the present study, elevated 
levels of LAP/proTGFβ–1 were supported by immunoblotting using an 
antibody that targets LAP (Figure 3c). Secondly, elevated levels of mature 
TGFβ–1 were corroborated by immunoblotting using an antibody that targets 
the actual TGFβ–1 domain (Figure 3d). Finally, N–terminal degradomics 
showed TGFβ–1 activation (see corresponding section). Collectively, these 
findings suggest increased TGFβ–1 signaling. 
 
TGFβ–1 signaling is known to cause increased L1CAM expression (Kiefel et 
al., 2012). We corroborated L1CAM levels elevated by immunoblotting 
(Figure 3e). There are two possible reasons for the raised levels of the shed 
L1CAM ectodomain: increased cell-surface proteolysis (with subsequent 
depletion of membrane bound L1CAM) or elevated levels of cell-associated 
L1CAM possibly representing higher L1CAM expression. Western blotting 
showed higher cell-associated levels of L1CAM (Figure 3e) suggesting its 
increased expression. 
 
Importantly, elevated levels of LAP/proTGFβ–1 and L1CAM upon expression 
of KLK 4–7 were corroborated in vivo by immunohistochemical analysis of 
tumor xenografts derived from an ovarian cancer animal model (Loessner et 
al., 2013) (Figure 4).  
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The cellular phenotype of the KLK4–7 co-expressing ovarian cancer cells also 
supports increased levels of TGFβ–1 signaling. These cells are less adhesive 
and more invasive than their wild type counterparts (Loessner et al., 2012; 
Prezas et al., 2006). In good agreement, expression of KLK4 in PC3 prostate 
cancer cells leads to a more migratory phenotype (Veveris-Lowe et al., 2005). 
Similarly, expression of KLK6 in murine keratinocytes results in a more 
migratory and invasive behavior (Klucky et al., 2007). In epithelial cells, 
TGFβ–1 is known to induce a more motile cellular phenotype (Kalluri and 
Weinberg, 2009), which is considered a hallmark of TGFβ–1 signaling. A 
prototypical feature of TGFβ–1 signaling is loss of epithelial cadherin (E-
cadherin) expression. However, previous studies have determined that the 
OV-MZ-6 cell line does not express E-cadherin ab initio and represents the 
advanced disease stage (Loessner et al., 2012; Loessner et al., 2010). 
 
In summary, our quantitative secretome analysis shows elevated 
LAP/proTGFβ–1 expression in OV-MZ-6 cells co-expressing KLK4–7. This is 
validated in vivo using tumor xenografts. Several lines of evidence further 
support elevated TGFβ–1 signaling, including identification of mature, 
bioactive TGFβ–1, increased L1CAM expression, and a previously identified 
more motile cellular phenotype (Loessner et al., 2012; Prezas et al., 2006). 
proTGFβ–1 activation by KLK proteases has been proposed (Emami and 
Diamandis, 2007; Matsumura et al., 2005). Our study shows a strong 
association between KLK expression and TGFβ–1 signaling in a cellular 
context.  
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3.2 Quantitative Profiling of Proteolytic Cleavage Sites  
To identify cleavage events that are overrepresented upon expression of KLK 
4–7, Terminal Amine Isotopic Labeling of Substrates (TAILS) was used 
(Kleifeld et al., 2010). TAILS is a proteomic method that specifically analyzes 
protein N-termini, including proteolytically generated N-termini. Through stable 
isotopic labeling, the N-terminome of kallikreins 4–7 co-expressing OV–MZ-6 
cells was quantitatively compared to the N-terminome of the corresponding 
control cells. More specifically, this analysis focuses on the cellular secretome. 
 
3.2.1 Overview and Overlap of Individual TAILS Replicates 
Two replicates were performed for the N-terminal analysis based on CCM 
from OV–MZ–6 cells that express KLK 4–7 in comparison to OV–MZ–6 vector 
control cells. These experiments identified and quantified 2,435 and 1,402 
protein N-termini respectively (Sup. Tables S5, S6). Based on GO and 
SwissProt annotation, 41 % and 34 % map to secreted and/or cell surface-
associated proteins. These fractions are slightly elevated compared to the 
quantitative proteome profiling, possibly indicating the importance of 
proteolysis as a posttranslational modification in the extracellular milieu.  
 
Most N-termini display Fc-values (log2 of light:heavy ratio) close to 0 
indicating that they were not quantitatively affected by expression of KLK4–7 
(Figure 5). This observation is in line with the global proteome comparison, 
which also highlights that kallikreins 4–7 expression does not lead to an 
excessive increase in bulk proteolysis. Both replicates showed few cleavage 
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sites with Fc-values < -2. At the same time, there was a substantial amount of 
cleavage sites with Fc-values > +2. This bias indicates an elevated proteolytic 
processing in the cellular microenvironment upon expression of KLK4–7, 
despite the aforementioned absence of excessively increased bulk proteolysis. 
 
The two TAILS experiments display an overlap of 589 N-termini (Figure 5c). 
The quantitation (as displayed by the corresponding Fc-values) of these 589 
shared identification shows good reproducibility with a correlation coefficient 
of 0.71 (data not shown). This number is in line with the correlation 
coefficients that were determined for the replicates of the global proteome 
analysis. 
 
3.2.2 Kallikreins 4–7 Expression Yields a “Post-Arginine” Specificity 
Fingerprint. 
Proteolytic enzymes have characteristic specificities. As outlined by Debela et 
al (Debela et al., 2008), KLK4, KLK5 and KLK6 preferentially cleave C-
terminal to arginine whereas KLK7 displays chymotryptic specificity (preferred 
cleavage C-terminal to aliphatic and aromatic residues). Borgono et al 
corroborate KLK4–7 specificity (Borgoño et al., 2007). At the same time, 
Debela et al. as well as Yoon et al. have shown that KLK7 cleaves post 
arginine despite its chymotryptic preference (Debela et al., 2006; Yoon et al., 
2007). In the present study, the majority of enriched cleavage sites (Fc-value 
> 1) in both replicates occurred C-terminal to an arginine residue (Figure 6) 
and only few chymotryptic cleavage sites were observed. This specificity 
fingerprint corresponds well to the annotated preference of KLK4, KLK5 and 
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KLK6, and possibly also KLK7. These findings strongly indicate a prominent 
KLK activity in the secretome of KLK4–7 co-transfected OV–MZ–6 cells. The 
high representation of trypsin–like as opposed to chymotrypsin–like activity is 
not surprising since 3 of the 4 enzymes (KLK4/5/6) have predominant tryptic 
activity. 
 
3.2.3 Identification of Putative KLK Cleavage Sites 
Proteolysis in OV–MZ cell conditioned medium was profiled to identify 
putative KLK substrates. Strict criteria were chosen to select neo-N-termini as 
possible KLK cleavage sites:  
• neo-N-terminus identified in both replicates (589 cleavage sites) 
• maps to a protein that is annotated as being secreted or cell surface-
associated according to GO or SwissProt annotation (236 of the 589 
cleavage sites) 
• quantitatively enriched upon KLK expression (Fc–value > 1.0, 91 of the 
236 cleavage sites) 
• cleavage occurs C–terminal to an arginine (KLK4, KLK5, KLK6, and 
possibly also KLK7 specificity) or aromatic residues (KLK7 specificity); 
our analysis was restricted to canonical KLK specificity (Debela et al., 
2008) (61 of the 91 cleavage sites).  
• corresponding protein levels are not found to be elevated in global 
secretome comparison 
• neo-N-terminus does not represent removal of signal peptide or initiator 
methionine 
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14 cleavage sites in a total of 12 different proteins entirely fulfill these strict 
criteria and represent putative KLK substrates (Figure 7). Kallikrein 
dependent proteolytic processing of several cell signaling proteins was 
observed, including growth differentiation factor 15 (GDF–15), macrophage 
inhibitory factor (MIF), semaphorin 3C and stanniocalcin-1. With the exception 
of agrin, kallikrein dependent proteolysis was not observed for matricelullar 
proteins or ECM components. The focus on cell-cell communication was in 
line with the results obtained by global proteomic comparison. Together, both 
findings strengthen the notion of proteolysis being a regulatory event in 
cancer cell biology. 
 
To a large extent, KLK dependent proteolytic events appear to occur in 
structurally accessible sites, including domain linker regions present in agrin, 
annexin A2 and tyrosine-protein kinase receptor UFO. Similarly, N- and C-
terminal regions of proteins are often structurally accessible. In this context, 
N-terminal processing of cathepsin Z and semaphorin 3C likely occurs at a 
structurally accessible site. Proteolysis at structurally accessible sites does 
not necessitate prior unfolding, and thus, suggests a regulatory rather than a 
degradative function. 
 
Cleavage sites in proprotein convertase 1 inhibitor (PCSKI), platelet-derived 
growth factor subunit A (PDGFA) and stanniocalcin-1 occur after several 
basic residues (arginine or lysine). Such sites are typically considered to be 
targeted by furin-like proteases, a group which includes proprotein 
convertases. Specificity profiling of KLK4–6 showed that only KLK6 has a 
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pronounced preference for pairs of basic residues (Borgoño et al., 2007; 
Debela et al., 2008). The present analysis cannot distinguish increased furin-
like activity as a downstream effect of initial KLK activity. However, the 
specificity fingerprints (Figure 6) do not show an increased occurrence of 
cleavage sites at dibasic motives but rather support increased activity of 
trypsin-like KLK proteases. 
 
Using a cell model of ovarian cancer, our data shows proteolytic remodeling 
of the cellular microenvironment by KLK proteases, with a prominent focus on 
proteins mediating cellular communication. It is beyond the scope of the 
present work to determine the functional consequences stemming from KLK 
dependent proteolytic processing. However, it has been shown that proteases 
can inactivate or functionally convert chemokines through proteolytic 
processing and generation of stable cleavage products (Broxmeyer et al., 
2012; McQuibban et al., 2000). 
 
3.2.4 TGFβ–1 Maturation 
Global quantitative proteomic comparison strongly indicates a pronounced 
effect of KLK expression on TGFβ–1 levels and subsequent TGFβ signaling 
(see corresponding section). In good agreement, the N-terminomic analysis 
revealed substantially elevated amounts of the mature N-terminus of the 
TGFβ–1 cytokine domain (Figure 8). As stated above, increased occurrence 
of mature TGFβ–1 most likely reflects an elevated abundance of the 
precursor form rather than increased proteolytic processing. The 
corresponding identification of mature TGFβ–1 cytokine domain by N-TAILS 
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complements this finding and points to increased levels of bioactive TGFβ–1 
rather than a sheer accumulation of its inactive precursor. 
 
4 Conclusion 
This study focused on the impact of KLK4–7 expression in the OV-MZ-6 
ovarian cancer cells as numerous studies suggest that KLKs are associated 
with ovarian cancer. This study addresses the contribution of kallikreins in 
shaping the cellular microenvironment. The proteomic and degradomic 
analyses highlight the absence of excessively increased bulk proteolysis but 
rather support the notion of proteolysis being a regulatory event in cell-cell 
communication. For example, KLK4–7 expression leads to elevated levels of 
the pro-inflammatory proteins CXCL1 and MCSF–1. Putative KLK substrates 
include cytokines, such as GDF-α and MIF. Both experimental setups 
corroborate induced TGFβ–1 signaling. While global secretome comparison 
showed elevated levels of LAP/proTGFβ–1, TAILS revealed substantially 
elevated amounts of the mature N-terminus of the TGFβ–1 cytokine domain, 
underlining the increased levels of bioactive TGFβ–1, which possibly result in 
the previously described more motile phenotype of kallikrein 4–7 co-
expressing OV–MZ–6 cells (Loessner et al., 2012; Prezas et al., 2006). This 
study emphasizes the major impact of KLK proteases on the extracellular 
proteome in the tumor microenvironment of ovarian cancer. 
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Figure Legends 
Figure 1: (a-c) Distribution of fold–change values (log2 of light:heavy ratios) 
for the three replicate global proteome comparison experiments. (d) Overlap 
of the three replicate global proteome comparison experiments. 928 proteins 
were consistently identified and quantified in all three experiments.  
 
Figure 2: Peptide mapping for collagen XVIII. Tryptic collagen XVIII peptides 
that were identified in the global secretome comparison are mapped on the 
collagen XVIII sequence. In all three replicates, peptides cluster in the C-
terminal non-collagenous region, which encompasses the anti-angiogenic 
cleavage product endostatin. S, signal peptide; NC, non–collagenous domain. 
The color scale indicates the Fc–values of the individual peptides. 
 
Figure 3:  
(a,b) Western blot detection of PEDF and thrombospondin–1 in cell 
conditioned medium. 30 µg proteome were used with a 12.5 % reducing 
SDS–PAGE.  
 38 
(c) Western blot detection of LAP/TGFβ–1 in cell conditioned medium. 8 µg 
proteome were used with a 12.5 % reducing SDS–PAGE. The primary 
antibody was directed against the LAP domain (prodomain). In line with 
previous reports (Dubois et al., 1995), the ∼55 kDa band is thought to 
represent proTGFβ–1 whereas the predominant ∼40 kDa band is thought to 
represent LAP. The elevated size in comparison to the primary sequence is 
thought to stem from glycosylation (Brunner et al., 1992; Dubois et al., 1995).  
(d) Western blot detection of mature TGFβ–1 (disulfide linked dimer) in cell 
conditioned medium. 30 µg proteome were used with a 12.5 % non–reducing 
SDS–PAGE. The primary antibody was directed against the actual TGFβ–1 
domain. In addition, N–terminal degradomics showed TGFβ–1 activation (see 
corresponding section).  
(e) Western blot detection of L1CAM in cell conditioned medium (CCM) and 
total cell lysate, including cell surface proteins. 8 µg (CCM) and 12 µg 
proteome (total cell lysate), respectively, were separated with a 7.5 % 
reducing SDS–PAGE. The molecular weight of 220 kDa for L1CAM is higher 
than expected but in line with previous reports (Li and Galileo, 2010).  
 
Figure 4: Immunohistochemical detection of TGFβ-1 and L1CAM expression 
in xenografts derived from mice bearing KLK4-7 co-transfected OV-MZ-6 cell 
and control tumors. A positive staining for both proteins was detected in the 
cytoplasm, with a more intense staining upon KLK 4-7 expression. Scale bars, 
50 µm. 
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Figure 5: (a-b) Distribution of fold–change values (log2 of light:heavy ratios) 
for the two replicate N-terminomic experiments. (c) Overlap of the two 
replicate N-terminomic experiments. 589 cleavage sites were consistently 
identified and quantified in both experiments.  
 
Figure 6: Specificity fingerprint of cleavage sites that are induced by 
expression of KLK4–7 (quantile 80 – 100). The white line depicts the scissile 
peptide bond. The X-axis shows amino acid positions in relation to the 
cleavage site. Schechter and Berger nomenclature was used (Schechter and 
Berger, 1966). Heat map generated as described previously (Schilling et al., 
2011). Sequence logos were generated with the iceLogo software (Colaert et 
al., 2009). 
 
Figure 7: Putative substrates of KLK4–7. Cleavage sites are annotated by 
arrows. Criteria for selection of cleavage sites are described in the text. 
Abbreviations used: A, annexin– like; C1, peptidase C1 domain; GDF, growth 
differentiation factor; E, epidermal growth factor– like; Fn, fibronectin type III–
like; I: immunoglobulin I-set–like; K, kazal–like; L, laminin–like; MIF, 
macrophage migration inhibitory factor; MHC, major histocompatibility 
complex–like; Nta, N-terminal agrin; P, prodomain; PCSKI, proprotein 
convertase 1 inhibitor; PDGFA, platelet-derived growth factor subunit A; Pk, 
protein tyrosine kinase–like; PV; platelet-derived growth factor–like / vascular 
endothelial growth factor–like; Sem, semaphorin–like; St: stanniocalcin–like; T, 
transmembrane; Tb, transforming growth factor–β–like; Tf: transferrin– like. 
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Figure 8: The N-terminus of mature TGFβ–1 was identified in both TAILS 
replicates with elevated abundance upon combined expression of KLK4–7. 
The tandem mass spectra of the identified sequence 
ALDTNYCFSSTEKNCCVR (N-terminus of mature TGFβ–1) is shown. This 
finding corroborates elevated levels of mature, bioactive TGFβ–1. 
 
Table 1: Significantly affected proteins by KLK4-7 expression. Uniprot ID and 
recommended name according to Uniprot database (Uniprot Consortium, 
2013). p-value denotes the significance of a protein being quantitatively 
affected. p–values of individual experiments were calculated by ASAPratio (Li 
et al., 2003) and combined using Fisher’s method, resulting in a merged p–
value. The cut off of 0.1 was chosen in agreement with the ASAPratio original 
publication (Li et al., 2003). Fc–value (log2 of light:heavy ratio) denotes the 
average Fc–value of the three replicates with the corresponding standard 
deviation value in the following column. 
 
Sup. Table S1: Identified and quantified proteins in the first replicate of global 
secretome comparison. All proteins have a ProteinProphet probability score > 
0.90, equivalent to an FDR < 0.01. Ratios are normalized to KLK expression / 
control. 
 
Sup. Table S2: Identified and quantified proteins in the second replicate of 
global secretome comparison. All proteins have a ProteinProphet probability 
score > 0.90, equivalent to an FDR < 0.01. Ratios are normalized to KLK 
expression / control. 
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Sup. Table S3: Identified and quantified proteins in the third replicate of 
global secretome comparison. All proteins have a ProteinProphet probability 
score > 0.90, equivalent to an FDR < 0.01. Ratios are normalized to KLK 
expression / control. 
 
Sup Table S4: Proteins that are identified and quantified in all three replicates 
of global proteome comparison. Averaged ratios are normalized to KLK 
expression / control. 
 
Sup Table S5: Analysis of N-termini that were unmodified upon secretome 
harvest and chemically dimethylated in the TAILS procedure (replicate 1). 
This is a non-redundant, peptide-centric list, showing up to three proteins for 
each peptide identification. The X! Tandem hyperscore and the mass 
deviation in ppm are shown. The overall FDR is < 0.05 as calculated by 
PeptideProphet. The prime sequence was experimentally identified, the 
corresponding non-prime sequence was bioinformatically derived. The fold-
change (Fc) value is based on ASAPratio. 
 
Sup Table S6: Analysis of N-termini that were unmodified upon secretome 
harvest and chemically dimethylated in the TAILS procedure (replicate 2). 
This is a non-redundant, peptide-centric list, showing up to three proteins for 
each peptide identification. The X! Tandem hyperscore and the mass 
deviation in ppm are shown. The overall FDR is < 0.05 as calculated by 
PeptideProphet. The prime sequence was experimentally identified, the 
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corresponding non-prime sequence was bioinformatically derived. The fold-
change (Fc) value is based on ASAPratio. 
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From proteomics: more LAP/TGFb1 in KLK expressing cells. CONFIRMED! 
The 37 kDa form is LAP together with the C-terminal TGFb1 domain. 
The 50 kDa form: maybe glycosylated? 
The 75 kDa form from cell lysate: ignore, not of relevance for us. Could be a false positive. 
Importantly, we do not see LAP alone (ca 25 kDa). Combine this info with our proteomic results/peptide 
mapping. 
Maybe try deglycosylation? 
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28.08.13 GPM  -­  peptide  model:  4358.1.1  of  sp|P01137|TGFB1_HUMAN
localhost:8082/thegpm-­cgi/peptide.pl?ltype=&path=/tandem/archive/H_TC4.tandem.xml&uid=17353&label=sp|P01137|TGFB1_HUMAN&homolog=17353&id=4… 1/2
    
peptide  model:  4358.1.1  of  sp|P01137|TGFB1_HUMAN
|  model   |  protein  |  homologues   |  XML  |  gpmDB  |  wiki   |  
sp|P01137|TGFB1_HUMAN:  no  protein  information  ava i lable
Sample  information
# log(e) log(I) m+h delta ζ sequence  |  va l idate  |  s tudio  |  mgf  |  deta i l s   |
4358 -­‐3.2 4.61 2293.0682 0.0055 3/3 rhrr279  ALDTNYCFSSTEKNCCVR296qlyi     (98)  
   mods: 285C+57.0215,  293C+57.0215,  294C+57.0215,  291K+34.0631,  279A+34.0631
H_MB_TC4_P101211_040112.mzXML  scan  4358  (charge  3)
A L D T N Y C F S S T E K N C C V R
0 200 400 600 800 1000 1200 1400
0
20
40
60
80
100
m/z
RI
view:
-­0.3 0.3
error  (Da)
matched/total: #  ions :  34% intens i ty:  40% σ:  0.20  Da
bond +1y +1y-­‐17 +1y-­‐18 +1b +1b-­‐17 +1b-­‐18 +2y +2y-­‐17 +2y-­‐18 +2b +2b-­‐17 +2b-­‐18
A1 2187.968 2170.942 2169.958 106.107 89.081 88.097 1094.488 1085.974 1085.482 53.557 45.044 44.552
L2 2074.884 2057.857 2056.873 219.192 202.165 201.181 1037.946 1029.432 1028.940 110.099 101.586 101.094
D3 1959.857 1942.831 1941.847 334.218 317.192 316.208 980.432 971.919 971.427 167.613 159.100 158.608
T4 1858.809 1841.783 1840.799 435.266 418.240 417.256 929.908 921.395 920.903 218.137 209.623 209.131
N5 1744.766 1727.740 1726.756 549.309 532.283 531.299 872.887 864.374 863.882 275.158 266.645 266.153
Y6 1581.703 1564.677 1563.693 712.372 695.346 694.362 791.355 782.842 782.350 356.690 348.177 347.685
C7 1421.672 1404.646 1403.662 872.403 855.377 854.393 711.340 702.827 702.335 436.705 428.192 427.700
F8 1274.604 1257.578 1256.593 1019.472 1002.445 1001.461 637.806 629.292 628.800 510.239 501.726 501.234
S9 1187.572 1170.545 1169.561 1106.504 1089.477 1088.493 594.290 585.776 585.284 553.755 545.242 544.750
S10 1100.540 1083.513 1082.529 1193.536 1176.509 1175.525 550.774 542.260 541.768 597.271 588.758 588.266
T11 999.492 982.466 981.482 1294.583 1277.557 1276.573 500.250 491.737 491.245 647.795 639.282 638.790
E12 870.450 853.423 852.439 1423.626 1406.599 1405.615 435.729 427.215 426.723 712.317 703.803 703.311
K13 708.292 691.265 690.281 1585.784 1568.757 1567.773 354.649 346.136 345.644 793.396 784.882 784.390
N14 594.249 577.222 576.238 1699.827 1682.800 1681.816 297.628 289.115 288.623 850.417 841.904 841.412
C15 434.218 417.192 416.207 1859.858 1842.831 1841.847 217.613 209.099 208.607 930.432 921.919 921.427
C16 274.187 257.161 256.177 2019.888 2002.862 2001.878 137.597 129.084 128.592 1010.448 1001.934 1001.442
V17 175.119 158.092 157.108 2118.957 2101.930 2100.946 88.063 79.550 79.058 1059.982 1051.469 1050.977
Other  observed  ions:
Ion  type m/z Ion  type m/z
by[10-­‐14] 594.331 ay[5-­‐9] 644.250
by[4-­‐8] 686.260 ay[8-­‐13] 686.393
ay[2-­‐7] 739.308 by[12-­‐18] 981.482
Residue  modification  sets  tested:
Complete  mods: i .   Carbamidomethyl@C,  34.063117@[,  34.063117@K
N-­‐terminal: i .   Ammonia-­‐loss@Q,  Ammonia-­‐loss@C,  Dehydrated@E  (peptide)
i i .   ragged,  Acetyl   (protein)
Peptide  found  in  the  following  protein:
1.  sp|P01137|TGFB1_HUMAN
Transforming  growth  factor  beta-­‐1
OS=Homo  sapiens   GN=TGFB1...
no  protein  information  ava i lable
Contributor: anonymous
Adobe  SVG  plugin  may  be  required.  
TNYCF STEKNCCVR (replicate 2)
27.08.13 GPM  -­  peptide  model:  6339.1.1  of  sp|P01137|TGFB1_HUMAN
localhost:8082/thegpm-­cgi/peptide.pl?ltype=&path=/tandem/archive/H_HC9_.tandem.xml&uid=17353&label=sp|P01137|TGFB1_HUMAN&homolog=17353&id=… 1/2
    
peptide  model:  6339.1.1  of  sp|P01137|TGFB1_HUMAN
|  model   |  protein  |  homologues   |  XML  |  gpmDB  |  wiki   |  
sp|P01137|TGFB1_HUMAN:  no  protein  information  ava i lable
Sample  information
# log(e) log(I) m+h delta ζ sequence  |  va l idate  |  s tudio  |  mgf  |  deta i l s   |
6339 -­‐7.8 4.46 2293.0682 -­‐0.0057 2/3 rhrr279  ALDTNYCFSSTEKNCCVR296qlyi     (98)  
   mods: 285C+57.0215,  293C+57.0215,  294C+57.0215,  291K+34.0631,  279A+34.0631
H_MB_HC9_P310112_070212.mzXML  scan  6339  (charge  2)
A L D T N Y C F S S T E K N C C V R
0 300 600 900 1200 1500 1800
0
20
40
60
80
100
m/z
RI
view:
-­0.3 0.3
error  (Da)
matched/total: #  ions :  56% intens i ty:  68% σ:  0.18  Da
bond +1y +1y-­‐17 +1y-­‐18 +1b +1b-­‐17 +1b-­‐18
A1 2187.968 2170.942 2169.958 106.107 89.081 88.097
L2 2074.884 2057.857 2056.873 219.192 202.165 201.181
D3 +21959.857 1942.831 1941.847 334.218 317.192 316.208
T4 +1,21858.809 1841.783 1840.799 435.266 418.240 417.256
N5 1744.766 1727.740 1726.756 549.309 532.283 531.299
Y6 +1,21581.703 1564.677 1563.693 712.372 695.346 694.362
C7 1421.672 1404.646 1403.662 872.403 855.377 854.393
F8 1274.604 1257.578 1256.593 1019.472 1002.445 1001.461
S9 +1,21187.572 1170.545 1169.561 1106.504 1089.477 1088.493
S10 1100.540 1083.513 1082.529 1193.536 1176.509 1175.525
T11 999.492 982.466 981.482 1294.583 1277.557 1276.573
E12 870.450 853.423 852.439 +21423.626 1406.599 1405.615
K13 708.292 691.265 690.281 1585.784 1568.757 1567.773
N14 594.249 577.222 576.238 1699.827 1682.800 1681.816
C15 434.218 417.192 416.207 1859.858 1842.831 1841.847
C16 274.187 257.161 256.177 2019.888 2002.862 2001.878
V17 175.119 158.092 57.108 +22118.957 2101.930 2100.946
Other  observed  ions:
Ion  type m/z Ion  type m/z
by[10-­‐14] 594.331 by[7-­‐12] 712.261
(parent-­‐R)+2 1059.982 by[3-­‐11] 1076.399
(parent-­‐NH3)
+2 1138.524 ay[5-­‐16] 1557.634
a[13] 1557.784 by[5-­‐16] 1585.629
Residue  modification  sets  tested:
Complete  mods: i .   Carbamidomethyl@C,  34.063117@[,  34.063117@K
N-­‐terminal: i .   Ammonia-­‐loss@Q,  Ammonia-­‐loss@C,  Dehydrated@E  (peptide)
i i .   ragged,  Acetyl   (protein)
Peptide  found  in  the  following  protein:
1.  sp|P01137|TGFB1_HUMAN
Transforming  growth  factor  beta-­‐1
OS=Homo  sapiens   GN=TGFB1...
no  protein  information  ava i lable
Contributor: anonymous
YCF STEKNCCVR (replicate 1)
m/zm/z
-0.3   0.3
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Shahinian et al., Table 1 
  
Uniprot  p-value Fc-value Std. dev. Name 
P41222 0.000 4.1 0.8 Prostaglandin-H2 D-isomerase 
Q7Z7G0 0.000 4.4 1.1 Target of Nesh-SH3 
P33908 0.000 -2.4 0.4 Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA 
P26022 0.000 3.4 0.2 Pentraxin-related protein PTX3 
O43405 0.000 3.7 1.1 Cochlin 
P36955 0.000 3.6 0.3 Pigment epithelium-derived factor (PEDF) 
P24592 0.001 3.1 1.1 Insulin-like growth factor-binding protein (IGFBP) 6 
P05997 0.001 4.9 0.5 Collagen alpha-2(V) chain 
P09341 0.001 2.5 1.6 Growth-regulated α protein (Gro−α, C-X-C motif chemokine 1, CXCL1) 
P17936 0.001 2.7 1.3 Insulin-like growth factor-binding protein (IGFBP) 3 
P07711 0.002 2.2 0.2 Cathepsin L1 
P53634 0.002 2.2 0.3 Dipeptidyl peptidase 1 
P01034 0.003 1.9 0.2 Cystatin-C 
P10646 0.003 2.1 0.1 Tissue factor pathway inhibitor 
Q9UBG0 0.004 -2.6 0.9 C-type mannose receptor 2 
Q08629 0.004 2.1 0.5 Testican-1 
P49746 0.004 2.4 0.9 Thrombospondin-3 
P55268 0.004 2.7 0.8 Laminin subunit β-2 
P49755 0.005 1.6 1.1 Transmembrane emp24 domain-containing protein 10 
P13987 0.005 1.7 0.5 CD59 glycoprotein 
O00300 0.009 -3.6 1.7 Osteoprotegerin 
O94907 0.009 2.1 0.5 Dickkopf-related protein (DKK)−1 
P01024 0.010 2.2 0.6 Complement C3 
P32004 0.010 2.0 0.3 Neural cell adhesion molecule L1 
Q9H3T2 0.013 -1.4 1.3 Semaphorin-6C 
P12109 0.015 1.9 0.6 Collagen α-1(VI) chain 
Q96EU7 0.015 2.1 2.4 C1GALT1-specific chaperone 1 
Q99542 0.025 1.6 0.5 Matrix metalloproteinase-19 
P09603 0.027 1.6 1.4 Macrophage colony-stimulating factor (MCSF)−1 
O95407 0.033 1.5 0.4 Tumor necrosis factor receptor superfamily member 6B 
Q9BTY2 0.038 1.5 0.5 Plasma alpha-L-fucosidase 
P01137 0.041 1.6 0.5 Transforming growth factor (TGF)β-1 
Q14563 0.042 1.7 0.2 Semaphorin-3A 
P02786 0.043 1.9 0.1 Transferrin receptor protein 1 
Table
Uniprot  p-value Fc-value Std. dev. Name 
Q5JRA6 0.047 1.4 0.6 Melanoma inhibitory activity protein 3 
Q08380 0.062 1.6 0.6 Galectin-3-binding protein 
P39060 0.062 1.7 0.6 Collagen alpha-1(XVIII) chain (contains endostatin peptide) 
P08236 0.068 2.3 0.6 Beta-glucuronidase 
P07996 0.073 -1.6 0.0 Thrombospondin-1 
P10321 0.075 1.7 0.6 HLA class I histocompatibility antigen, Cw-7 alpha chain 
Q969P0 0.076 -1.6 0.7 Immunoglobulin superfamily member 8 
Q9UNW1 0.081 1.8 0.6 Multiple inositol polyphosphate phosphatase 1 
Q6P4A8 0.082 1.4 0.6 Phospholipase B-like 1 
Q9NS15 0.095 1.8 0.2 Latent-transforming growth factor beta-binding protein (LTGFBP) 3 
P14625 0.095 1.5 0.2 Endoplasmin 
 
 
